Wenli Zhou1,2,3, Zhengpeng Li2,4, Huiqing Jiang5, Jingnan Li6, Rongrong Ren2, Xuefeng Gao7,8, Jianfeng Li2,3, Xin Wang4, Weifeng Wang9, Yunsheng Yang10,11. 1. School of Medicine, Nankai University, Tianjin, 300190, China. 2. Micriobiota Division, Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China. 3. School of Medicine, Chinese PLA General Hospital, Beijing, 100853, China. 4. Institute of Plant Protection and Microbiology, Zhejiang Academy of Agricultural Sciences, Hangzhou, 310021, China. 5. Department of Gastroenterology, The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang, 050000, China. 6. Department of Gastroenterology, Peking Union Hospital, Beijing, 100005, China. 7. Department of Gastroenterology and Hepatology, Shenzhen University General Hospital, Shenzhen, 518055, China. 8. Clinical Medical Academy, Shenzhen University, Shenzhen, 518060, China. 9. Micriobiota Division, Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China. wangphd126@126.com. 10. Micriobiota Division, Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China. sunnyddc@plagh.org. 11. National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, 100853, China. sunnyddc@plagh.org.
Abstract
BACKGROUND: The fecal microbiota in pancreatic ductal adenocarcinoma (PDAC) and in autoimmune pancreatitis (AIP) patients remains largely unknown. We aimed to characterize the fecal microbiota in patients with PDAC and AIP, and explore the possibility of fecal microbial biomarkers for distinguishing PDAC and AIP. METHODS: 32 patients with PDAC, 32 patients with AIP and 32 age- and sex-matched healthy controls (HC) were recruited and the fecal microbiotas were analyzed through high-throughput metagenomic sequencing. Alterations of fecal short-chain fatty acids were measured using gas chromatographic method. RESULTS: Principal coordinate analysis (PCoA) revealed that microbial compositions differed significantly between PDAC and HC samples; whereas, AIP and HC individuals tended to cluster together. Significant reduction of phylum Firmicutes (especially butyrate-producing bacteria, including Eubacterium rectale, Faecalibacterium prausnitzii and Roseburia intestinalis) and significant increase of phylum Proteobacteria (especially Gammaproteobacteria) were observed only among PDAC samples. At species level, when compared with HC samples, we revealed 24 and 12 differently enriched bacteria in PDAC and AIP, respectively. Functional analysis showed a depletion of short-chain fatty acids synthesis associated KO modules (e.g. Wood-Ljungdahl pathway) and an increase of KO modules associated with bacterial virulence (e.g. type II general secretion pathway). Consistent with the downregulation of butyrate-producing bacteria, gas chromatographic analysis showed fecal butyrate content was significantly decreased in PDAC group. Eubacterium rectale, Eubacterium ventrisum and Odoribacter splanchnicus were among the most important biomarkers in distinguishing PDAC from HC and from AIP individuals. Receiver Operating Characteristic analysis showed areas under the curve of 90.74% (95% confidence interval [CI] 86.47-100%), 88.89% (95% CI 73.49-100%), and 76.54% (95% CI 52.5-100%) for PDAC/HC, PDAC/AIP and AIP/HC, respectively. CONCLUSIONS: In conclusion, alterations in fecal microbiota and butyrate of patients with PDAC suggest an underlying role of gut microbiota for the pathogenesis of PDAC. Fecal microbial and butyrate as potential biomarkers may facilitate to distinguish patients with PDAC from patients with AIP and HCs which worth further validation.
BACKGROUND: The fecal microbiota in pancreatic ductal adenocarcinoma (PDAC) and in autoimmune pancreatitis (AIP) patients remains largely unknown. We aimed to characterize the fecal microbiota in patients with PDAC and AIP, and explore the possibility of fecal microbial biomarkers for distinguishing PDAC and AIP. METHODS: 32 patients with PDAC, 32 patients with AIP and 32 age- and sex-matched healthy controls (HC) were recruited and the fecal microbiotas were analyzed through high-throughput metagenomic sequencing. Alterations of fecal short-chain fatty acids were measured using gas chromatographic method. RESULTS: Principal coordinate analysis (PCoA) revealed that microbial compositions differed significantly between PDAC and HC samples; whereas, AIP and HC individuals tended to cluster together. Significant reduction of phylum Firmicutes (especially butyrate-producing bacteria, including Eubacterium rectale, Faecalibacterium prausnitzii and Roseburia intestinalis) and significant increase of phylum Proteobacteria (especially Gammaproteobacteria) were observed only among PDAC samples. At species level, when compared with HC samples, we revealed 24 and 12 differently enriched bacteria in PDAC and AIP, respectively. Functional analysis showed a depletion of short-chain fatty acids synthesis associated KO modules (e.g. Wood-Ljungdahl pathway) and an increase of KO modules associated with bacterial virulence (e.g. type II general secretion pathway). Consistent with the downregulation of butyrate-producing bacteria, gas chromatographic analysis showed fecal butyrate content was significantly decreased in PDAC group. Eubacterium rectale, Eubacterium ventrisum and Odoribacter splanchnicus were among the most important biomarkers in distinguishing PDAC from HC and from AIP individuals. Receiver Operating Characteristic analysis showed areas under the curve of 90.74% (95% confidence interval [CI] 86.47-100%), 88.89% (95% CI 73.49-100%), and 76.54% (95% CI 52.5-100%) for PDAC/HC, PDAC/AIP and AIP/HC, respectively. CONCLUSIONS: In conclusion, alterations in fecal microbiota and butyrate of patients with PDAC suggest an underlying role of gut microbiota for the pathogenesis of PDAC. Fecal microbial and butyrate as potential biomarkers may facilitate to distinguish patients with PDAC from patients with AIP and HCs which worth further validation.
Authors: Paul B Eckburg; Elisabeth M Bik; Charles N Bernstein; Elizabeth Purdom; Les Dethlefsen; Michael Sargent; Steven R Gill; Karen E Nelson; David A Relman Journal: Science Date: 2005-04-14 Impact factor: 47.728
Authors: L D Dickerson; A Farooq; F Bano; J Kleeff; R Baron; M Raraty; P Ghaneh; R Sutton; P Whelan; F Campbell; P Healey; J P Neoptolemos; V S Yip Journal: World J Surg Date: 2019-06 Impact factor: 3.352
Authors: James J Farrell; Lei Zhang; Hui Zhou; David Chia; David Elashoff; David Akin; Bruce J Paster; Kaumudi Joshipura; David T W Wong Journal: Gut Date: 2011-10-12 Impact factor: 23.059
Authors: Janelle C Arthur; Ernesto Perez-Chanona; Marcus Mühlbauer; Sarah Tomkovich; Joshua M Uronis; Ting-Jia Fan; Barry J Campbell; Turki Abujamel; Belgin Dogan; Arlin B Rogers; Jonathan M Rhodes; Alain Stintzi; Kenneth W Simpson; Jonathan J Hansen; Temitope O Keku; Anthony A Fodor; Christian Jobin Journal: Science Date: 2012-08-16 Impact factor: 47.728
Authors: Dominique S Michaud; Jacques Izard; Charlotte S Wilhelm-Benartzi; Doo-Ho You; Verena A Grote; Anne Tjønneland; Christina C Dahm; Kim Overvad; Mazda Jenab; Veronika Fedirko; Marie Christine Boutron-Ruault; Françoise Clavel-Chapelon; Antoine Racine; Rudolf Kaaks; Heiner Boeing; Jana Foerster; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Carlotta Sacerdote; Sabina Sieri; Domenico Palli; Rosario Tumino; Salvatore Panico; Peter D Siersema; Petra H M Peeters; Eiliv Lund; Aurelio Barricarte; José-María Huerta; Esther Molina-Montes; Miren Dorronsoro; J Ramón Quirós; Eric J Duell; Weimin Ye; Malin Sund; Björn Lindkvist; Dorthe Johansen; Kay-Tee Khaw; Nick Wareham; Ruth C Travis; Paolo Vineis; H Bas Bueno-de-Mesquita; Elio Riboli Journal: Gut Date: 2012-09-18 Impact factor: 23.059
Authors: Tommaso Schepis; Sara S De Lucia; Enrico C Nista; Vittoria Manilla; Giulia Pignataro; Veronica Ojetti; Andrea Piccioni; Antonio Gasbarrini; Francesco Franceschi; Marcello Candelli Journal: J Clin Med Date: 2021-12-17 Impact factor: 4.241